Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.891 EUR -2.14% Market Closed
Market Cap: 604.4m EUR

Pharming Group NV
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharming Group NV
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Pharming Group NV
AEX:PHARM
Cost of Revenue
-$30.3m
CAGR 3-Years
8%
CAGR 5-Years
-6%
CAGR 10-Years
-29%
ProQR Therapeutics NV
NASDAQ:PRQR
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Cost of Revenue
-$26.5m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Cost of Revenue
-$230.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Cost of Revenue
-$3.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Pharming Group NV
Glance View

Market Cap
604.6m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
HIDDEN
Show

See Also

What is Pharming Group NV's Cost of Revenue?
Cost of Revenue
-30.3m USD

Based on the financial report for Sep 30, 2024, Pharming Group NV's Cost of Revenue amounts to -30.3m USD.

What is Pharming Group NV's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-29%

Over the last year, the Cost of Revenue growth was -24%. The average annual Cost of Revenue growth rates for Pharming Group NV have been 8% over the past three years , -6% over the past five years , and -29% over the past ten years .

Back to Top